-
Oct 4, 2023 | 
frontiersin.org | Gregory A. Vidal
1 IntroductionBreast cancer is the most prevalent cancer in women worldwide and one of the leading causes of death among women in the United States and worldwide (1–3). Patients with advanced breast cancer may present with de novo metastatic disease in a proportion of patients that varies in different health care systems, significantly more in low-income countries (4).
-
Aug 22, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: Any other exciting medications that we didn’t talk about? Maybe an exciting endocrine drug that you think we should probably know about or look out for [in] the future? Timothy Pluard, MD: I think just the ones that we have we’re still awaiting the SERD [selective estrogen receptor degrader] to emerge. Some have fallen by the wayside, but we still need to get 1 across the finish line in addition to elacestrant [Orserdu].
-
Aug 22, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: We have these 2 exciting ADCs [antibody-drug conjugates] now for our patients in clinic, both with survival benefit. We have trastuzumab deruxtecan [T-DXd], and we use that with patients who had at least 1 line of chemotherapy, [with] no more than 2 lines of chemotherapy. And that’s based on HER2-low status.
-
Aug 15, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: Continuing that thought process about checking HER and then thinking about an ADC [antibody-drug conjugate] trastuzumab deruxtecan [T-DXd] for HER2-low [breast cancer], we also have sacituzumab govitecan [Trodelvy]. What do you think about TROP-2 [Trophoblast cell surface antigen 2] expression, and what is your idea about the TROPiCS-02 trial [NCT03901339]? Maybe you can speak to both the TROP-2 expression, whether you want to use that as a biomarker.
-
Aug 15, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: One thing that I really wanted to talk about, not just therapies in this setting, but how do we test for these mutations? We spoke about ESR [estrogen signaling receptor] when we spoke about PI3K [mutations], AKT mutations, and HER2 mutations. How do we think about testing? Do you use tissue [or] do you use plasma, and why?
-
Aug 8, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: Greg, maybe you can address this as well. What has your experience been with alpelisib? How do you use it? And where do you use it? In what setting for HR-positive disease? And let’s say CAPItello tomorrow is going to be approved and you have that scenario, how are you thinking about both these trials, both these medications? What are you offering your patients and why?
-
Aug 8, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: At the ASCO [American Society of Clinical Oncology] meeting this year, they presented data from the MORPHEUS study [NCT04802759]. Do you want to tell us about that study? What do you think about those data and how will that be relevant in our second-line setting? Aditya Bardia, MD, MPH: Yes, in principle, it was similar.
-
Aug 1, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: Switching over from our first-line metastatic setting where we’ve definitely now established that we use CDK4/6 inhibitors and novel SERDs [selective estrogen receptor disruptors] might be a good endocrine partner of choice in the future based on these trials.
-
Aug 1, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: One of the burning questions that we always have in the first line is [about] our young premenopausal women, and [how] they have aggressive tumor biology and don’t necessarily have the same outcomes that we would expect for others. Should we offer them chemotherapy? Can you walk us through the evidence about what you do [with] your patients and why? Timothy Pluard, MD: That’s been an ongoing debate about somebody who has visceral involvement.
-
Jul 25, 2023 | 
onclive.com | Komal Jhaveri |Aditya Bardia |VK Gadi |Timothy J. Pluard |Gregory A. Vidal
Transcript:Komal Jhaveri, MD, FACP: One of the interesting data sets that were presented today, actually, were very, very provocative. Very nice question. A very academically designed study, which I think was very helpful. Certainly, when it was designed, [it’s] very, very important to address. I would love to hear your thoughts, Greg, about the phase 3 SONIA trial [NCT03425838] from our Dutch colleagues that was presented today.
